A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial
Titel:
A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial
Auteur:
Cook, Jonathan A Patten, Piers E M Peckham, Nicholas Moss, Paul Phillips, Neil Abhishek, Abhishek Roberts, Thomas Hodges, Marie Talbot, Georgina Barber, Vicki Francis, Anne Shields, Adrian M Duley, Lelia Hoogeboom, Robbert Willett, Brian J Scott, Sam Parry-Jones, Nilima Eyre, Toby A Plested, Gareth Vandici, Gratian Wandroo, Farooq Ahmad Hutchinson, Claire Paneesha, Shankara Murray, Duncan J Martinez-Calle, Nicolas Jenkins, Stephen Heartin, Earnest Parry, Helen M
Verschenen in:
The Lancet. Haematology
Paginering:
Jaargang 12 () nr. 4 pagina's e294-e303
Jaar:
2025
Inhoud:
Uitgever:
The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.